More Follow-Up Suggested After Removing Pancreatic Cysts

Video

Data suggests a more scrutinized follow-up period following surgery.

New research suggests closer and more expansive follow-up for patients who had pancreatic cysts surgically removed.

In data presented at the annual American College of Gastroenterology (ACG) 2020 virtual meeting, a team of doctors from the Cleveland Clinic described the post-surgical course of pancreatic cyst patients, while evaluating the rates and predictors of recurrent cysts, high-risk, and malignant transformation over a 5 year review of existing data.

In an interview with HCPLive®, Mohannad Abou Saleh, MD and Prabhleen Chahal, MD, explained how the review might ultimately result in a change in the guidelines to closely monitor these patients for longer periods of time.

In the cohort, the investigators examined data from 104 patients who underwent surgical intervention for pancreatic cysts with 37 (37.4%) cases undergoing pancreaticoduodenectomy and 62 (62.6%) undergoing distal pancreatectomy.

At the one-year mark following surgery, 34.5% had recent cysts with 5.1% with high-risk transformation and 11.7% malignant transformation. By year 5, these rates increased to 64.8%, 13.7%, and 19%, respectively.

The overall mortality rate was 13.5%, with 5.8% related to pancreatic causes over the 5 year review period.

Chahal explained how this study shows how most guidelines and practices should be constantly updated and examined as more information and data comes out.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.